Kao C.-N.TUNG-HUNG SUJIA-HORNG KAO2021-03-092021-03-0920170269-2813https://www.scopus.com/inward/record.uri?eid=2-s2.0-85008319323&doi=10.1111%2fapt.13872&partnerID=40&md5=fa25ba65f4aecd9d9cbde7f4900e5959https://scholars.lib.ntu.edu.tw/handle/123456789/551096[SDGs]SDG3entecavir; hepatitis B surface antigen; interferon; peginterferon; virus RNA; alpha interferon; antivirus agent; hepatitis B surface antigen; hepatitis B(e) antigen; interferon; recombinant protein; virus DNA; delta agent hepatitis; drug hypersensitivity; drug safety; drug withdrawal; Hepatitis B virus; Hepatitis delta virus; human; Letter; liver cirrhosis; liver injury; nonhuman; priority journal; treatment duration; treatment response; treatment withdrawal; viral clearance; chronic hepatitis B; delta agent hepatitis; genetics; kinetics; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Interferon-alpha; Interferons; Kinetics; Recombinant Proteinsletter10.1111/apt.13872280430912-s2.0-85008319323